6. パーキンソン病 Parkinson disease Clinical trials / Disease details


臨床試験数 : 2,298 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

  
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01007864
(ClinicalTrials.gov)
January 20103/11/2009Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine AgonistsInfluence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine AgonistsIdiopathic Parkinson's DiseaseDrug: piribedil;Drug: pramipexole or ropiniroleDesitin Arzneimittel GmbHFGK Clinical Research GmbHCompleted35 Years80 YearsBoth80Phase 3Germany
2EUCTR2009-012419-16-DE
(EUCTR)
03/12/200920/10/2009Influence of the Non-Ergot Dopamine agonist Piribedil on vigilance and cognitive function in patients with Parkinson's disease compared to other oral Non-Ergot Dopamine agonists - PIVICOG-PDInfluence of the Non-Ergot Dopamine agonist Piribedil on vigilance and cognitive function in patients with Parkinson's disease compared to other oral Non-Ergot Dopamine agonists - PIVICOG-PD idiopathic Parkinson's disease
MedDRA version: 12.0;Level: PT;Classification code 10061536;Term: Parkinson's disease
Trade Name: Clarium 50 mg Retardtabletten
INN or Proposed INN: piribedil
Desitin Arzneimittel GmbHNULLNot RecruitingFemale: yes
Male: yes
Germany
3ChiCTR-TRC-12002150
2009-09-292012-05-06Study on Optimization of The Comprehensive Therapeutic Plan for Parkinson's Disease in Different StagesStudy on Optimization of The Comprehensive Therapeutic Plan by Stages for Parkinson's Disease Parkinson's DiseaseThe early treatment group:Xifeng Dingchan Pill;The early control group:Madopar tablets;Interim treatment group:Xifeng Dingchan Pill, Madopar tablets and Piribedil tablets;Henan University of Traditional Chinese MedicineNULLRecruiting5075BothThe early treatment group:80;The early control group:80;Interim treatment group:160;China
4NCT01519856
(ClinicalTrials.gov)
June 200912/3/2010PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term TherapyEfficacy and Safety of Long-term Therapy With Piribedil (CLARIUM) in Patients With M. Parkinson Under Consideration of Quality of Life Parameters and Cognitive FunctionParkinson's DiseaseDrug: piribedil (Clarium)Desitin Arzneimittel GmbHNULLCompleted18 YearsN/ABoth908N/AGermany
5NCT00727727
(ClinicalTrials.gov)
March 200831/7/2008SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices.Parkinson's DiseaseDrug: PiribedilDesitin Arzneimittel GmbHNULLCompleted18 YearsN/ABoth750N/AGermany
6NCT00725478
(ClinicalTrials.gov)
January 200828/7/2008SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's DiseaseStabilization on, or Change-over to the Non-ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Parkinson Clinic Ambulances and Larger Private Practices.Parkinson's DiseaseDrug: PiribedilDesitin Arzneimittel GmbHNULLCompleted18 YearsN/ABoth250N/ANULL
7EUCTR2005-000314-12-DE
(EUCTR)
19/12/200625/01/2007Effect of 3 doses ( 20, 40 and 60 mg) of a sublingual formulation of piribedil ( S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson's disease patients after a 14 day treatment-period ( one administration t.i.d). A randomized, double-blind study consisting of 3 cross-over: 40 mg versus placebo, 20 mg versus 60 mg and 40 mg versus 20 mg. - PARKOPIEffect of 3 doses ( 20, 40 and 60 mg) of a sublingual formulation of piribedil ( S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson's disease patients after a 14 day treatment-period ( one administration t.i.d). A randomized, double-blind study consisting of 3 cross-over: 40 mg versus placebo, 20 mg versus 60 mg and 40 mg versus 20 mg. - PARKOPI Parkinson's Disease aggravated
MedDRA version: 7.0;Level: LLT;Classification code 10034006
Product Name: S90049
Product Code: S90049
INN or Proposed INN: piribedil
Product Name: S90049
Product Code: S90049
INN or Proposed INN: piribedil
Institut de Recherches Internationales ServierNULLNot RecruitingFemale: yes
Male: yes
80Phase 2Spain;Germany
8EUCTR2005-002010-38-DE
(EUCTR)
21/11/200510/02/2006Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot studyAssessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot study Advanced Parkinson´s DiseaseProduct Name: Trivastal
Product Code: S 90049
INN or Proposed INN: Piribedil
Institut de Recherches Internationales Servier (I.R.I.S.)NULLNot RecruitingFemale: yes
Male: yes
80Germany
9EUCTR2005-000314-12-ES
(EUCTR)
14/10/200508/09/2005Effect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil (S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson’s disease patients after a 14-day treatment-period (one administration t.i.d.). A randomised, double-blind study consisting of 3 cross-over: 40 mg versus placebo, 20 mg versus 60 mg and 40 mg versus 20 mg. - PARKOPIEffect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil (S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson’s disease patients after a 14-day treatment-period (one administration t.i.d.). A randomised, double-blind study consisting of 3 cross-over: 40 mg versus placebo, 20 mg versus 60 mg and 40 mg versus 20 mg. - PARKOPI Parkinson's Disease aggravated
MedDRA version: 7.0;Level: LLT;Classification code 10034006
Product Name: piribedil
Product Code: S 90049 - F36
INN or Proposed INN: piribedil
Product Name: piribedil
Product Code: S 90049 - F38
INN or Proposed INN: piribedil
Institut de Recherches Internationales ServierNULLNot RecruitingFemale: yes
Male: yes
80Phase 2Spain;Germany